ABOUT ATTRALUS

DEEP EXPERIENCE IN AMYLOID RESEARCH, THERAPEUTIC DEVELOPMENT & COMMERCIALIZATION

A COMPANY BRINGING NEW POSSIBILITIES

Attralus aims to transform the lives of patients with amyloidosis with therapeutics that remove toxic amyloid.

We are advancing a pipeline of novel biologics designed for pan-amyloid removal – across all stages and types of systemic amyloidosis. In support of our paradigm-changing therapeutics, we are also developing the world’s first amyloidosis-specific diagnostic imaging agent which has the potential to set a new standard in the diagnosis of systemic amyloid and identify the many patients that remain undiagnosed.

Moving Fast with a Focus on Patients in Need

There are currently no treatments to remove amyloid in patients with systemic amyloidosis. Current treatments are applicable for some types of amyloidosis and reduce new amyloid formation which may slow disease progression. However, none of these existing therapies directly address the toxic amyloid already deposited in organs that leads to progressive organ failure and increased mortality.

Attralus is Advancing New Solutions

We are focused on addressing this unmet need for an amyloidosis therapy capable of broadly removing existing amyloid deposits, opening the door to improving organ function and reversing disease for patients with all types of systemic amyloidosis.

Management Team

Our team of leading amyloidosis scientists and experts has researched and developed systemic amyloidosis therapeutics for more than 25 years.

photo of Mark Timney

Mark Timney

CHIEF EXECUTIVE OFFICER

photo of greg bell - CMO

Gregory Bell, MD

CHIEF MEDICAL OFFICER

photo of Glen Firestone CBO

Glen Firestone

CHIEF BUSINESS OFFICER

photo of Spencer Guthrie CO-FOUNDER & CHIEF OPERATING OFFICER

Spencer Guthrie

CO-FOUNDER & CHIEF OPERATING OFFICER

photo of Krishna Gorti, MD HEAD OF CORPORATE DEVELOPMENT

Krishna Gorti, MD

HEAD OF CORPORATE DEVELOPMENT

James Testa, Vice President of Finance

James Testa

VICE PRESIDENT, FINANCE

Photo of Michael L. Klein, PhD HEAD OF CMC

Michael L. Klein, PhD

SVP, CMC

Photo of Christine Huh head of human resources

Christine Huh

HEAD OF HUMAN RESOURCES

Jonathan Wall, PhD CO-FOUNDER & INTERIM CHIEF SCIENTIFIC OFFICER

Jonathan Wall, PhD

CO-FOUNDER & INTERIM CHIEF SCIENTIFIC OFFICER

Board of Directors

Knowledgeable business leaders and investors with demonstrated experience in building and scaling biotechnology companies.

Photo of Corey Goodman MANAGING PARTNER, VENBIO

Corey Goodman

MANAGING PARTNER, VENBIO

Photo of Richard Gaster, MD, PHD MANAGING PARTNER, VENBIO

Richard Gaster, MD, PHD

MANAGING PARTNER, VENBIO

Photo of Nancy Miller-Rich INDEPENDENT

Nancy Miller-Rich

INDEPENDENT

Photo of Rahul Kakkar, MD INDEPENDENT

Rahul Kakkar, MD

INDEPENDENT

Photo of Jake Bauer INDEPENDENT

Jake Bauer

INDEPENDENT

Photo of Alexander Denner, PhD INDEPENDENT

Alexander Denner, PhD

SARISSA CAPITAL

photo of Mark Timney

Mark Timney

CHIEF EXECUTIVE OFFICER

Scientific Advisory Board

Attralus has assembled a world-class team of clinical and scientific advisors that includes recognized experts in amyloids, drug discovery, and clinical development.

Photo of Jaume Pons, PhD

Jaume Pons, PhD

CEO, ALX ONCOLOGY

Photo of Jeff Kelly, PhD SCRIPPS RESEARCH INSTITUTE

Jeff Kelly, PhD

SCRIPPS RESEARCH INSTITUTE

Photo of Morie Gertz, MD MAYO CLINIC

Morie Gertz, MD

MAYO CLINIC

Photo of Mathew Maurer, MD COLUMBIA UNIVERSITY / NEW YORK PRESBYTERIAN

Mathew Maurer, MD

COLUMBIA UNIVERSITY / NEW YORK PRESBYTERIAN

Investors

Logo for venBio
Logo for Sarissa Capital Management LP
Alpha Wave Global logo
Logo for Redmile Group
Logo for Janus Henderson Investors
Bristol Myers Squibb logo
Logo for Logos Capital
Logo for Surveyor
Logo for Vivo Capital
Logo for Samsara Biocapital